FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer’s Disease
LifeProNow
MAY 17, 2023
These symptoms are leading causes of assisted living or nursing home placement and have been associated with accelerated disease progression.” The supplemental approval of Rexulti was granted to Otsuka Pharmaceutical Company Ltd., director of the Division of Psychiatry in the FDA’s Center for Drug Evaluation and Research.
130 
Let's personalize your content